
    
      This trial is a phase 3 study to evaluate efficacy and safety of co-administrated
      Rosuvastatin/Ezetimibe and Telmisartan in patients with primary hypercholesterolemia and
      essential hypertension.

      In "Rosuvastatin/Ezetimibe+Telmisartan" treatment group, 60 subjects will be assigned and the
      subjects administer "Rosuvastatin/Ezetimibe+Telmisartan" for 8 weeks.

      In "Rosuvastatin/Ezetimibe" treatment group, 60 subjects will be assigned and the subjects
      administer "Rosuvastatin/Ezetimibe" for 8 weeks.

      In "Telmisartan" treatment group, 60 subjects will be assigned and the subjects administer
      "Telmisartan" for 8 weeks.
    
  